Folic acid and phenytoin metabolism. 1971

P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen

UI MeSH Term Description Entries
D008862 Microsomes, Liver Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough. Liver Microsomes,Liver Microsome,Microsome, Liver
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D005492 Folic Acid A member of the vitamin B family that stimulates the hematopoietic system. It is present in the liver and kidney and is found in mushrooms, spinach, yeast, green leaves, and grasses (POACEAE). Folic acid is used in the treatment and prevention of folate deficiencies and megaloblastic anemia. Pteroylglutamic Acid,Vitamin M,Folacin,Folate,Folic Acid, (D)-Isomer,Folic Acid, (DL)-Isomer,Folic Acid, Calcium Salt (1:1),Folic Acid, Monopotassium Salt,Folic Acid, Monosodium Salt,Folic Acid, Potassium Salt,Folic Acid, Sodium Salt,Folvite,Vitamin B9,B9, Vitamin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001161 Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. Arterioscleroses
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
January 1995, The Annals of pharmacotherapy,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
July 1981, Lancet (London, England),
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
January 1983, Clinical pharmacy,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
June 1973, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
April 1984, Drug intelligence & clinical pharmacy,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
March 1995, Journal of the American Dietetic Association,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
January 1978, Drug metabolism and disposition: the biological fate of chemicals,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
January 1992, Epilepsia,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
January 1983, Therapeutic drug monitoring,
P B Andreasen, and J M Hansen, and L Skovsted, and K Siersbaek-Nielsen
January 1983, Therapeutic drug monitoring,
Copied contents to your clipboard!